Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
15 June 2023 - 9:47PM
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company
developing innovative, full-length multispecific antibodies
(Biclonics® and Triclonics®), today announced the appointment of
Greg Perry as the Company’s Chief Financial Officer (CFO).
Additionally, Greg has been designated as the Company’s principal
financial officer, succeeding Bill Lundberg, M.D., in such role. In
connection with his appointment as the Company’s Chief Financial
Officer, on June 14, 2023, Greg resigned from the Company’s Board
of Directors.
“I am excited to welcome Greg as our CFO and
look forward to drawing from his broad biotech experience in
capital finance and strategic transactions, and deep knowledge of
our business,” said Bill Lundberg, M.D., President, Chief Executive
Officer of Merus. “Greg brings industry-leading financial acumen
and has been a great source of insight on the Merus Board of
Directors. I’m looking forward to working with him full time as we
continue to advance the Company through the exciting opportunities
that lie ahead.”
Greg Perry has served as a non-executive director of the Merus
Board of Directors since May 2016 and Vice Chair of the Board since
August 2018. Greg remains a non-executive director of the Board of
Directors of Kala Pharmaceuticals, a role he has held since March
2018. Prior to joining Merus, Greg was the CFO of Finch
Therapeutics from May 2018 through April 2022. Previously Greg held
various senior financial leadership roles at several biotech
companies including Novelion Therapeutics, Eleven Biotherapeutics,
ImmunoGen, Domantis, and Transkaryotic Therapies. Greg transitioned
to the biotech industry after beginning his career at General
Electric, where he served in increasingly senior financial roles
over fourteen years. He earned a B.A. in Economics and Political
Science from Amherst College.
“I am delighted to join the team at Merus, during this
compelling next chapter for the Company, following the truly
remarkable petosemtamab interim clinical data presented this Spring
at AACR, as we move to a later-stage clinical development company,
with a terrific pipeline and compelling platform,” said Greg Perry,
CFO, Merus.
About Merus N.V.Merus is a clinical-stage
oncology company developing innovative full-length human bispecific
and trispecific antibody therapeutics, referred to as
Multiclonics®. Multiclonics® are manufactured using industry
standard processes and have been observed in preclinical and
clinical studies to have several of the same features of
conventional human monoclonal antibodies, such as long half-life
and low immunogenicity. For additional information, please
visit Merus’ website and Twitter.
Forward Looking StatementThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation, statements regarding the
opportunities that lie ahead for the Company, the move to a
later-stage clinical development company, the advancement of the
Company’s pipeline and platform, and Mr. Perry’s anticipated
contribution to the organization. These forward-looking statements
are based on management’s current expectations. These statements
are neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including,
but not limited to, the following: our need for additional funding,
which may not be available and which may require us to restrict our
operations or require us to relinquish rights to our technologies
or antibody candidates; potential delays in regulatory approval,
which would impact our ability to commercialize our product
candidates and affect our ability to generate revenue; the lengthy
and expensive process of clinical drug development, which has an
uncertain outcome; the unpredictable nature of our early stage
development efforts for marketable drugs; potential delays in
enrollment of patients, which could affect the receipt of necessary
regulatory approvals; our reliance on third parties to conduct our
clinical trials and the potential for those third parties to not
perform satisfactorily; impacts of the COVID-19 pandemic; we may
not identify suitable Biclonics® or bispecific antibody candidates
under our collaborations or our collaborators may fail to perform
adequately under our collaborations; our reliance on third parties
to manufacture our product candidates, which may delay, prevent or
impair our development and commercialization efforts; protection of
our proprietary technology; our patents may be found invalid,
unenforceable, circumvented by competitors and our patent
applications may be found not to comply with the rules and
regulations of patentability; we may fail to prevail in potential
lawsuits for infringement of third-party intellectual property; our
registered or unregistered trademarks or trade names may be
challenged, infringed, circumvented or declared generic or
determined to be infringing on other marks; and risks related to
our ceasing to qualify as an emerging growth company and a smaller
reporting company after December 31, 2021.
These and other important factors discussed under the caption
“Risk Factors” in our Quarterly Report on Form 10-Q for the period
ended March 31, 2023, filed with the Securities and Exchange
Commission, or SEC, on May 4, 2023, and our other reports filed
with the SEC, could cause actual results to differ materially from
those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management’s estimates as of the date of this press release. While
we may elect to update such forward-looking statements at some
point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change, except as required
under applicable law. These forward-looking statements should not
be relied upon as representing our views as of any date subsequent
to the date of this press release.
Multiclonics®, Biclonics® and Triclonics® are registered
trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
Investor Relations and Corporate Communications
617-230-4165
k.farren@merus.nl
Merus NV (NASDAQ:MRUS)
Historical Stock Chart
From Apr 2024 to May 2024
Merus NV (NASDAQ:MRUS)
Historical Stock Chart
From May 2023 to May 2024